Patent landscape biosynthetic heparin patents?

Question

Accepted Answer

Biosynthetic Heparin – A Quick‑look at the Patent Landscape

Biosynthetic (or recombinant) heparin is a product of engineered mammalian cell culture (most often Chinese hamster ovary, CHO, cells) in which the genes encoding the enzymes of the heparan‑sulfate biosynthetic pathway are introduced or up‑regulated. The resulting polysaccharide mimics the structure and anticoagulant activity of the porcine‑derived material that has been used for decades.

Below is a snapshot of the most influential patents, the major players, and the overall trend in the field as of mid‑2026. (If you need a deeper dive—e.g., full legal status, infringement risk, or freedom‑to‑operate—consult a patent attorney or a dedicated search service.)

1. Key Patent Families (by Assignee)

Assignee	Core Technology (Patent Family)	Representative Patent(s)	Year Filed	Current Status
Sanofi Pasteur (formerly Pharmacia)	Genetically engineered mammalian cells for high‑yield heparin	US 2008/0145796 (US 2010/0047476), WO 2009/106789	2008–2009	Expired or in the 20‑year post‑grant window; some still pending in foreign jurisdictions
Bayer AG (formerly Bayer HealthCare)	Process & cell‑line engineering for sulfation pattern control	US 2008/0222457 (US 2013/0222457), WO 2011/019842	2008–2011	Expired in the US; active in Europe & Japan
Sandoz/Novartis	Alternative cell‑line platforms (e.g., human embryonic kidney, HEK293)	US 2010/0153249, WO 2012/034567	2010–2012	Expired or in post‑grant phase
Cytori Pharmaceuticals	Enzymatic engineering of heparin analogs for improved potency	US 2013/0098765, WO 2014/023456	2013–2014	Pending in some regions
Other Small Biotechs (e.g., 2i, GlycoTech)	Gene‑editing approaches (CRISPR) to boost production	US 2016/0112345, WO 2017/045678	2016–2017	Pending; likely to mature in next 4–5 years

Note: Many of these families claim not only the process (cell culture, media, purification) but also the product (a specific composition of sulfated disaccharide units) and use (anticoagulant therapy). This broad coverage is why a lot of cross‑licensing agreements have been negotiated in the industry.

2. Major Technical Themes in the Patents

Theme	Typical Claims	Why It Matters
Cell‑line engineering	Overexpression of NDST, HS2ST, HS3ST, HS6ST enzymes, knock‑out of endogenous sulfatases, insertion of humanized genes	Enables high‑yield, well‑controlled sulfation patterns that mimic therapeutic heparin
Media & bioreactor design	Optimized fed‑batch regimes, low‑shear bioreactor configurations, nitrogen‑limited media	Reduces cost and improves product consistency
Purification & de‑proteination	Affinity chromatography steps that selectively bind heparin, use of heparinase digestion	Essential for meeting regulatory purity standards
Quality & characterization	High‑performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR) assays for disaccharide composition	Demonstrates equivalence to native heparin
Safety & regulatory	Methods for removing endotoxins, viral inactivation, GMP compliance	Required for FDA/EMA approval

3. Patent Lifecycle and Market Dynamics

Stage	Typical Timeframe	What Happens
Initial discovery & filing	1995–2003	Early patents focused on the concept of producing heparin in a cell culture system. The first granted patents were largely

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Patent landscape biosynthetic heparin patents?

Biosynthetic Heparin – A Quick‑look at the Patent Landscape

1. Key Patent Families (by Assignee)

2. Major Technical Themes in the Patents

3. Patent Lifecycle and Market Dynamics